

**Remarks**

Prior to this Amendment document, claims 1, 5, 9, 13, 15, 17, 19, 21, 23-27, and 38-60 were pending and stood rejection. Claims 5 and 9 are amended, and claims 13, 15, 17, 19, 21, 23-24, 47-58, and 60 are canceled without prejudice to their renewal in a subsequently filed patent application. Therefore, claims 1, 5, 9, 25-27, 38-46, and 59 are currently pending. Amended claim 5 defines the treating method of claim 1 as reducing a symptom associated with psoriasis. Support for this amendment is found throughout the specification, including from page 99, line 16 to page 100, line 5; from canceled claims 13, 15, 17, 19, and 21, which individually list symptoms associated with psoriasis. The limitations of the canceled claims have been added to amended claim 9. No new matter is added by these amendments.

The following remarks address each objection/rejection in the order in it was made.

**I. Formal Matters**

The specification was objected to due to the use of a hyperlink. Accordingly, the specification was amended at page 36 to remove the hyperlink. This objection may now be withdrawn.

**II. Rejections Under § 112, first paragraph.**

Claims 1, 5, 9, 13, 15, 17, 19, 21, 23-27, and 38-60 were rejected on the basis that the specification is “enabling for treating tumor growth using FltD2.FltD3.FcΔC1(a) and for treating psoriatic-like focal lesions in K14VEGF transgenic mice using VEGFR1R2-FcΔC1(a)” but not “for the treatment of psoriatic lesions, hyperproliferation of keratinocytes, epidermal hyperplasia, parakeratosis, microabcess, retidges, infiltration of lymphocytes, or all inflammatory skin diseases.”

This rejection is respectfully traversed. In order to satisfy the enablement requirement of § 112, the specification must adequately describe how to make and use the invention. Applicants

Appl. No. 09/773,877

Amendment dated 14 November 2003

Reply to Office Action of 25 August 2003

submit that the pending claims are sufficiently supported by the specification such that the enablement requirement of §112 is clearly met because the specification teaches how to make the VEGF antagonists of the invention, and the antagonists are tested and shown to be effective in an accepted animal model of human psoriasis.

First, the instant specification describes how to make each of these VEGF antagonists. Claim 1 is drawn to a method of treating psoriasis in a mammal comprising administering a VEGF antagonist to the mammal wherein the VEGF antagonist is selected from the group consisting of acetylated Flt-1(1-3)-Fc, Flt-1(1-3<sub>R->N</sub>)-Fc, Flt-1(1-3<sub>ΔB</sub>)-Fc, Flt-1(2-3<sub>ΔB</sub>)-Fc, Flt-1(2-3)-Fc, Flt-1D2-VEGFR3D3-FcΔC1(a), Flt-1D2-Flk-1D3-FcΔC1(a), and VEGFR1R2-FcΔC1(a), such that psoriasis is treated. All of the claimed VEGF antagonists are fully described in the specification as follows: Flt(1-3)-Fc is described in Fig. 10A-D and SEQ ID NOs:11-12; Flt1(1-3<sub>ΔB</sub>)-Fc is described in Fig. 13A-D and SEQ ID NOs:13-14; Flt1(2-3<sub>ΔB</sub>)-Fc is described at Fig. 14A-D and SEQ ID NOs:15-16; Flt1(2-3)-Fc is described in Fig. 15A-D and SEQ ID NOs:17-18'; Flt1(1-3<sub>R->N</sub>)-Fc is described in Fig. 16A-D and SEQ ID NOs:19-20; Flt1D2.Flk1D3.FcΔC1(a) is described in Fig. 21A-C and SEQ ID NOs:21-22; Flt1D2.VEGFR3D3.FcΔC1(a) is described in Fig. 22A-C and SEQ ID NOs:23-24; and VEGFR1R2-FcΔC1(a) is described in Fig. 24A-C and SEQ ID NOs:25-26.

Second, the specification describes experiments showing the ability of these molecules to bind VEGF. For example, Examples 6-7, 10, 18, 25, 26, 27, and 34 show the ability of these constructs to bind VEGF. Examples 8, 29 and 33 describe the pharmacokinetics of these molecules *in vivo*. Flt1D2.Flk1D3.FcΔC1(a) and Flt1(1-3)-Fc were tested in a tumor cell suspension system and shown to significantly reduce tumor growth (Example 30); VEGFR1R2-FcΔC1(a) was tested in an accepted animal model of human psoriasis and found to significantly reduce the psoriatic symptom examined.

Third, K14VEGF is an accepted animal model for human psoriasis. As described in the attached publication Xia et al. (2003) Blood 102:161-168, the K14VEGF transgenic mouse model is an accepted animal model for human psoriasis, exhibiting all of the symptoms associated with the human skin condition termed "psoriasis", including epidermal changes including thickening, altered

Appl. No. 09/773,877

Amendment dated 14 November 2003

Reply to Office Action of 25 August 2003

differentiation, rete ridge formation, papillomatosis; vascular changes such as dilation of papillary loops; and inflammatory changes such as epidermal T-cell infiltration and intra-epidermal microabcesses.

Fourth, the VEGF trap is shown to effectively reverses psoriatic disease. As described in the instant specification at page 109, an experiment was conducted to determine the effect of a VEGF antagonist of the invention on psoriatic lesions exhibited by K14VEGF transgenic mice. The results show that treatment with a VEGF antagonist significantly improved psoriatic skin lesions. This result is further supported by Xia et al. (2003) *supra*, that use of a VEGF trap eliminated the hyperplastic vascular phenotype, suppressed the associated inflammatory state, and reduced the levels of surrogate markers (such as E-selectin) of human psoriasis (Xia et al. (2003) at page 167, col. 2, first full paragraph).

The Examiner argues that the method of the claims requires undue experimentation. He cites *In re Wands*, 8 U.S.P.Q.2d 1400 (Fed. Cir. 1988) in support. But little, if any, experimentation is required here: to treat psoriasis, one administers to a patient one of the eight VEGF antagonists listed. The disease is specified (psoriasis). As is the cure (one of the VEGF antagonists). Everything one of ordinary skill in the art needs is enumerated within the claims. It is unclear why the Examiner believes that such claims are not enabled.

The claims here require far *less* experimentation than the Federal Circuit permitted in *Wands*, where the claims covered antibodies that the claims and specification did *not* enumerate, and where there was uncertainty, moreover, as to which antibodies one of skill in the art could use. The case illustrates the principle that even a “considerable amount of experimentation is permissible, if it is merely routine.” *PPG Industries, Inc. v. Guardian Industries Corp.*, 37 U.S.P.Q.2d 1618, 1623 (Fed. Cir. 1996); *Wands*, 8 U.S.P.Q.2d at 1404 (“The key word is ‘undue,’ not ‘experimentation.’”). But *Wands*, where the Federal Circuit reversed the Patent Office’s finding of non-enablement, is an extreme case compared to the present one, where everything one of ordinary skill in the art needs is enumerated within the claim itself. The Applicants respectfully submit that such claims are enabled. *Wands* does not establish anything to the contrary.

Applicants have amended the claims to clarify that the symptoms previously recited separately in claims 9, 13, 15, 17, 19, and 21, are all clinical symptoms associated with human psoriasis. Accordingly, claim 5 is amended to clarify that treating psoriasis results in reducing a symptom associated with psoriasis, and claim 9 is amended to define symptoms associated with psoriasis, including a psoriatic lesion, keratinocyte hyperproliferation, epidermal hyperplasia, parakeratosis, microabcess, and rete ridge formation. In light of the above remarks, it is believed that the enablement rejection should be withdrawn.

### **III. Rejections under 35 USC § 112, second paragraph.**

Claims 1, 5, 9, 13, 15, 17, 19, 21, 23-27, and 38-60 were rejected as indefinite for recitation of the terms “Flt” and “1(1-3)”, “R→N”, etc. The Examiner requested that the applicants point out specifically in the specification how the antagonists of claim 1 are defined. Accordingly:

(1) at page 8, lines 1-7, “Flt1” is defined as a VEGF receptor. Flt1 was known at the time the instant application was filed, for example, see DeVries et al. (1992) Science 255:989-991. Flt1 is also shown in a schematic diagram in Fig. 11;

(2) “Flt(1-3)-Fc” is described at page 43, line 15 to page 56, line 14, and shown in Fig. 10A-D, and SEQ ID NOS:11-13;

(3) “Flt1(1-3<sub>ΔB</sub>)-Fc” is described at page 56, line 19, to page 59, line 15, and shown in Figs. 13A-D, and SEQ ID NOS:13-14. Example 11 describes construction of the deletion mutant Flt1(1-3<sub>ΔB</sub>)-Fc from Flt(1-3)-Fc and identifies that amino acids 272-281 of Fig. 10 were deleted to generate the deletion mutant;

(4) “Flt1(2-3<sub>ΔB</sub>)-Fc” is described at page 59, line 20 to page 60, line 9, and shown in Fig. 14A-D, and SEQ ID NOS:15-16. Example 12 describes how the deletion mutant Flt1(2-3<sub>ΔB</sub>)-Fc was constructed by introduction of a restriction site (BspE1) at nucleotides 73-78;

(5) “Flt1(2-3)-Fc” is described at page 60, lines 14-20, and shown in Fig. 15A-D, and SEQ ID NOS:17-18. Example 13 describes Flt1(2-3)-Fc as constructed the same way as Flt1(2-3<sub>ΔB</sub>)-Fc except that the Flt1 Ig domain 3 was left intact without deletion of the basic amino acid region;

Appl. No. 09/773,877

Amendment dated 14 November 2003

Reply to Office Action of 25 August 2003

(6) "Flt1(1-3<sub>R→N</sub>)-Fc" is described at page 60, line 25 to page 61, line 8, and shown in Fig. 16A-D, and SEQ ID NOs:19-20. Example 14 describes the Flt1(1-3<sub>R→N</sub>)-Fc construct which has an N-glycosylation side introduced into the middle of the basic region of Flt1 domain 3 by changing nucleotides 824-825 from GA to AC;

(7) "Flt1D2.Flk1D3.FcΔC1(a)" is described at page 66, line 9 to page 68, line 14, and shown in Fig. 21A-C, and SEQ ID NOs:21-22;

(8) "Flt1D2.VEGFR3D3.FcΔC1(a)" is described at page 68, line 18 to page 71, line 11, and shown in Fig. 22A-C, and SEQ ID NOs:23-24; and


(9) "VEGFR1R2-FcΔC1(a)" is described at page 73, line 18 to page 74, line 3, and shown in Figs. 24A-C, and SEQ ID NOs:25-26.

Accordingly, in light of the above clarification, it is believed that this rejection should be withdrawn.

## Fees

This Amendment document is submitted in response to the Office Action dated 25 August 2003, which set a 3 month statutory period for response, to 25 November 2003. This paper is being submitted within the response period, accordingly no fee is due. Please charge this fee any additional fee deemed necessary to Deposit Account Number 18-0650.

Respectfully submitted

  
Valeta Gregg, Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400

## Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis

Yu-Ping Xia, Baosheng Li, Donna Hylton, Michael Detmar, George D. Yancopoulos, and John S. Rudge

**Gene therapy approaches involving vascular endothelial growth factor (VEGF) to promote therapeutic angiogenesis are under consideration for conditions ranging from ischemic heart disease to nonhealing skin ulcers. Here we make the surprising observation that the transgenic delivery of VEGF to the skin results in a profound inflammatory skin condition with many of the cellular and molecular features of psoriasis, including the characteristic vascular changes, epidermal al-**

terations, and inflammatory infiltrates. Even longstanding psoriatic disease remains dependent on the transgenic VEGF in this model because it can be effectively reversed by the addition of VEGF Trap, a potent VEGF antagonist. Previous attempts to faithfully replicate the psoriatic phenotype through the transgenic delivery of epidermal keratinocyte growth factors or inflammatory mediators generated phenotypes with only partial resemblance to human psoriasis, leaving

unanswered questions about the etiology of this disease. The ability of transgenic VEGF to induce a psoriasis-like phenotype suggests a new etiology and treatment approach for this disease and further substantiates emerging concerns about possible proinflammatory adverse effects that might be associated with therapeutic attempts to deliver VEGF. (*Blood*. 2003;102:161-168)

© 2003 by The American Society of Hematology

### Introduction

Vascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis, prompting recent efforts to therapeutically exploit this factor in conditions involving pathologically decreased blood flow, such as ischemic heart disease and nonhealing skin ulcers. Some recent studies,<sup>1-6</sup> however, have raised concerns about whether the delivery of VEGF could also have deleterious consequences. Here we make the surprising observation that chronic transgenic delivery of VEGF to the skin can result in a profound inflammatory condition with many of the cellular and molecular hallmarks of human psoriasis, such as hyperplastic and inflamed dermal blood vessels,<sup>7</sup> epidermal thickening (termed acanthosis) with aberrant keratinocyte differentiation,<sup>8</sup> and characteristic inflammatory infiltrates.<sup>9,10</sup>

It has long been known that the reddened appearance of psoriatic skin is caused by hyperplastic dermal blood vessels, that vascular changes occur early in this disease, and that levels of VEGF are elevated in psoriatic skin.<sup>7,11-13</sup> In addition, the dermal vessels in psoriasis appear to be highly abnormal in that they are hyperpermeable, contributing to the edema that characterizes psoriatic skin, and in that they express markers of an inflamed vasculature, such as E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intracellular adhesion molecule-1 (ICAM-1).<sup>14-16</sup> In addition, the levels of soluble adhesion molecules in the sera of psoriasis patients, particularly E-selectin, provide a valuable surrogate marker of disease severity and therapeutic efficacy of various treatments.<sup>17-20</sup> Despite this, most efforts at understanding the etiology of this disease have focused on the epidermal and inflammatory aberrations. In the abnormally thickened epidermis, the top layer (termed stratum corneum), usually consisting of

cornified keratinocytes lacking nuclei, instead contains cells with nuclei (termed parakeratosis). Furthermore, this keratinized upper layer is excessively thickened (termed hyperkeratosis). Most striking, the epidermis produces highly abnormal and characteristic fingerlike projections into the underlying dermis, termed rete ridges. The typical inflammatory cell infiltrate seen in psoriasis is composed of epidermal microabscesses, increased numbers of mast cells, neutrophils and macrophages in the dermis, and activated T cells in the dermis and epidermis.<sup>21,22</sup> T-cell subsets achieve a unique distribution as psoriasis evolves, with CD4<sup>+</sup> T cells congregating primarily in the dermis while CD8<sup>+</sup> T cells migrate from their normal dermal position to the epidermis, which is usually free of leukocytes.<sup>23,24</sup>

It is clear that psoriatic skin is a hotbed of epidermal growth factors and inflammatory mediators.<sup>23,25-30</sup> Supportive evidence of a key role for such mediators comes from patients who respond to immunosuppressive, anti-inflammatory, and antiproliferative therapies such as cyclosporine, methotrexate, tacrolimus, corticosteroids, and ultraviolet-light-activated psoralen. However, extensive efforts aimed at transgenically delivering inflammatory mediators or keratinocyte growth factors to the skin have not completely reproduced the psoriatic phenotype<sup>28,31-36</sup> (Figure 1), which has thus far only been faithfully modeled in animals by transplanting human psoriatic skin onto mice with severe combined immunodeficiency disease (SCID)<sup>10,23</sup> (Figure 1). Factors such as keratinocyte growth factor, transforming growth factor- $\alpha$  (TGF- $\alpha$ ), and interleukin-20 (IL-20) promote some degree of epidermal hyperplasia, in certain cases with associated inflammation, but fail to produce many of the hallmarks of human psoriasis.<sup>28,34,37,38</sup> Transgenic

From Regeneron Pharmaceuticals, Tarrytown, NY; and Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Charlestown.

Submitted December 16, 2002; accepted March 3, 2003. Prepublished online as *Blood First Edition Paper*, March 20, 2003; DOI 10.1182/blood-2002-12-3793.

Supported in part by National Institutes of Health/National Cancer Institute grants CA69184 and CA86410 (M.D.).

Reprints: Y.-P. Xia, Regeneron Pharmaceuticals, Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591; e-mail: yuping.xia@regeneron.com.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2003 by The American Society of Hematology

Model/ Procedure	Epidermal Changes			Vascular Changes		Inflammatory Changes		Injury Response	
	Thickening	Altered Differentiation	Rate Ridges	Closure of Papillary Loops	Epidermal T Cell Infiltrate	Inter-epidermal Micro- vesicles	"Koebner" Phenomenon	Percentage of Psoriasis-like Phenotype	
Natural Disease	Human Psoriasis	Y	Y	Y	Y	Y	Y	100%	
Xenotransplant	Human Psoriasis/SCID	Y	Y	Y	Y	Y	Y	100%	
Tumorigenic	K14-VEGF	Y	Y	Y	Y	Y	Y	100%	
	K14-VEGFR2	Y	Y	Y	Y	Y	Y	100%	
	K14-VEGFR3	Y	Y	Y	Y	Y	Y	100%	
	K14-DLX4	Y	Y	Y	Y	Y	Y	100%	
	Intradermal FN	Y	Y	Y	Y	Y	Y	100%	
	K14-EGF	Y	Y	Y	Y	Y	Y	100%	
	K14-TGF $\beta$	Y	Y	Y	Y	Y	Y	100%	
	K14-EGF $\alpha$	Y	Y	Y	Y	Y	Y	100%	
	K14-TRP $\alpha$	Y	Y	Y	Y	Y	Y	100%	
	K14-TRP $\beta$	Y	Y	Y	Y	Y	Y	100%	
	K14-TRP $\gamma$	Y	Y	Y	Y	Y	Y	100%	
Nontransgenic	CD19 <sup>-/-</sup>	Y	Y	Y	Y	Y	Y	100%	
Spontaneous Mutation	Flaky Skin	Y	Y	Y	Y	Y	Y	100%	

**Figure 1. Summary of various mouse models and their resemblance to human psoriasis.** The top line indicates whether characteristic changes are seen in human psoriasis (Y for yes, N for no). Other models are compared with the human standard and are blocked in green if they match human psoriasis or in red if they do not match. Question marks and the yellow blocks indicate that the feature in question was not examined. Note that only 2 models precisely match human psoriasis in all the features indicated here—a xenotransplantation model in which human psoriatic skin was transplanted onto a SCID mouse (second line) and the K14-VEGF transgenic mouse discussed (third line).

delivery of amphiregulin has resulted in the most promising transgenic model, but this model still lacks the characteristic rete ridge projections seen in human psoriasis, and it is also prone to papillomatosis, which is not typical in the human disease<sup>29</sup> (Figure 1). In addition, a chronic inflammatory skin condition developed in mice in which CD18 was knocked out, but only when the CD18-deficient 129/Sv mice were backcrossed onto the PL/J strain.<sup>30</sup> Again, these mice lacked the rete ridge structures that are highly characteristic of human psoriasis (Figure 1).

The problems with the above transgenic models of psoriasis raise the possibility that there is an upstream predisposition for psoriasis that can somehow be triggered so as to lead to the extremely diverse cytokine and growth factor abnormalities that drive psoriasis and that none of these individual downstream mediators is sufficient to induce the full spectrum of psoriatic disease. Consistent with the notion that psoriasis involves an underlying predisposition, the wounding of asymptomatic skin in psoriatic patients can trigger a complete psoriatic response adjacent to the wound, in a classic reaction termed the Koebner phenomenon.<sup>40</sup>

Our studies suggest that excess VEGF may provide just such a predisposition by inducing a vascular inflammatory response that then predisposes to more widespread tissue inflammation closely resembling the psoriatic state. We report that young mice transgenically overexpressing VEGF in the skin initially lack overt disease but have a predisposition such that wounding can elicit the psoriatic phenotype, analogous to the Koebner phenomenon in humans. In older transgenic mice, the condition progresses until a profound inflammatory skin condition spontaneously develops with many of the cellular and molecular hallmarks of psoriasis, from characteristic epidermal alterations including dramatic rete ridge formation to the inflammatory infiltrates typical of psoriasis. Even late-stage disease remains dependent on transgenic VEGF because it can be effectively reversed by the addition of a potent VEGF antagonist. The ability of transgenic VEGF to induce a psoriasis-like phenotype suggests a new etiology and treatment approach for this disease and further substantiates emerging concerns<sup>6</sup> about possible proinflammatory adverse effects that might be associated with therapeutic attempts to deliver VEGF.

## Materials and methods

### K14-VEGF transgenic mice

A keratin-14 (K14)-based expression vector and a mouse cDNA encoding VEGF<sub>164</sub> were used to generate K14-VEGF transgenic mice on the FVB

genetic background, as previously described<sup>41</sup>; mice homozygous for this transgene were used throughout the studies described here. All animals in the facility are cared for in accordance with the "Guide for the Care and Use of Laboratory Animals" (National Research Council, 1996).

### Tissue processing and immunostaining

Tissue from the K14-VEGF transgenic and wild-type littermate mice used in these studies was matched according to sex, age, and wound site. Fixed sections were immunostained with antimouse platelet-endothelial cell adhesion molecule-1 (PECAM-1) (CD31; BD PharMingen, San Diego, CA), antimouse CD4 (BD PharMingen), antimouse CD8 (BD PharMingen), antimouse F4/80 (Serotec, Oxford, England), or antimouse VEGF (R&D Systems, Minneapolis, MN) following the manufacturer's instructions. Stainings for keratinocyte proliferation and differentiation markers or leukocyte adhesion molecules were performed as previously described<sup>41</sup> with rabbit polyclonal antibody against mouse keratin 6 (K6) (Babco, Richmond, CA) and rat monoclonal antibodies against mouse E-selectin (CD62E), ICAM-1 (CD54), and VCAM-1 (CD106; BD PharMingen) using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA).

### Histology

Hematoxylin and eosin (H&E) staining and trichrome staining were performed according to protocols previously described.<sup>42</sup>

### Injection of VEGF Trap

VEGF Trap is a fusion of the immunoglobulin 2 domain of human VEGFR1, the immunoglobulin 3 domain of human VEGFR2, and the Fc domain of human immunoglobulin G1 (IgG1), creating a forced homodimer that binds VEGF with high affinity (dissociation equilibrium constant, 1.5 pM) and prolonged in vivo half-life (1–2 days in mice).<sup>43</sup> The 6-month-old K14-VEGF homozygous transgenic mice were treated by the systemic administration of VEGF Trap by subcutaneous injection at a site distant from the psoriatic skin. Mice were treated with either 25 mg/kg VEGF Trap or 12.5 mg/kg human IgG, corresponding to an equal molar concentration as a control, using an injection schedule of every 3 days for 12 days that resulted in a total of 4 injections per animal. Mouse ear tissue was harvested on day 14 for subsequent histologic analyses.

## Results

### Young K14-VEGF transgenic mice display a mild pre-psoriatic phenotype

As previously reported, K14-VEGF transgenic mice overexpressing VEGF in the epidermis are fertile and overtly healthy.<sup>2,4</sup>



**Figure 2. Psoriasisform phenotype.** Erythematous, scaly, and thickened skin lesions with associated edema develop in homozygote K14-VEGF transgenic mice older than 5 months.

However, the ear skin of mice homozygous for this transgene is visibly redder than that of their wild-type *FVB* littermates. By 3 months, occasional focal skin lesions begin to develop on the ear and, to a lesser extent, on the dorsal and lateral skin. This condition worsens with age such that pronounced skin lesions are observed on the ears, neck, and snout by 5 months of age, with lesions


characterized by erythematous and scaly skin (Figure 2). These lesions coincided with sites of highest expression of the VEGF transgene (data not shown).

An initial histologic screen of the ear skin from young K14-VEGF transgenic mice, at 3 months of age, revealed a mild and potentially pre-psoriatic phenotype in these young mice using standard H&E staining—that is, the epidermis of these mice exhibited moderate acanthosis (epidermal hyperplasia) (Figure 3B, left inset), focal parakeratosis (keratinocytes in the stratum corneum retain nuclei) (Figure 3B, left inset), and mild rete ridge formation on the ventral ear surface (Figure 3B, arrows), compared with age-matched control littermates (Figure 3A). In the dermal compartment, edema contributing to an approximately 2- to 3-fold increase in tissue thickness was observed in the K14-VEGF mice, as was inflammatory cell infiltration in the subepidermal dermis (Figure 3; compare panels A and B).

Consistent with high-level transgenic overexpression of VEGF in the epidermis of these mice, VEGF protein was observed in the epidermis (where it is produced) and on dermal microvessels (where it presumably accumulates after diffusion into the dermis) in patterns (Figure 3A-B; compare right insets), remarkably reminiscent of those seen in human psoriasis.<sup>12</sup>

#### Young K14-VEGF transgenic mice exhibit a dramatic Koebner-like psoriatic response to injury

In contrast to the mild changes seen under basal conditions, creation of an excisional wound in the dorsal ear skin of 3-month-old K14-VEGF transgenic mice resulted in dramatic invaginations of the epidermis on the ventral side of the ear apposing the wound.



**Figure 3. Histologic examination of ear skin from K14-VEGF transgenic mice, using H&E-stained tissue sections.** (A) Control, wild-type littermate. Left inset shows epidermis at higher magnification; while right inset shows epidermis is negative for VEGF immunostaining. (B) Transgenic mouse (3 months of age) with edema, mild rete ridge formation on the ventral ear surface (arrows), epidermal acanthosis (left inset), and VEGF immunostaining in epidermis and in dermal microvessels (right inset). (C) Wound-induced rete ridge formation in a 3-month-old VEGF transgenic mouse. (D) Six-month-old VEGF transgenic mice showed spontaneous extensive rete ridge formation and anastomosis. (E) Early-stage human psoriasis shown for comparison. (F) Fully developed human psoriasis shown for comparison. Panels E-F reproduced with permission from Elder et al<sup>46</sup> and Nickoloff and Wrone-Smith,<sup>23</sup> respectively. Original magnifications:  $\times 10$  (A-D); and  $\times 40$  (insets).

These invaginations resembled the prominent rete ridge structures present in early human psoriasis (Figure 3E) and were observed in all 10 mouse ears used in the wounding study. Five ears were quantified for rete ridge counts (Figure 3C; Table 1). The induction of rete ridge formation in human pre-psoriatic skin has also been documented after skin injury and is termed the Koebner phenomenon.<sup>40</sup> Accompanying these rete ridge structures were increased dermal cellularity (inflammatory infiltrate), hyperkeratosis, and focal parakeratosis. These data suggest that to induce a severe psoriatic phenotype in the 3-month-old K14-VEGF transgenic animals, it would be necessary to introduce another stimulus such as wounding. This is consistent with the clinical evolution from pre-psoriatic skin to psoriatic lesion in humans (Koebner phenomenon).


#### Dramatic psoriasiform epidermal lesions spontaneously develop in older K14-VEGF mice

As the K14-VEGF transgenic mice aged, they spontaneously began to develop dramatic lesions resembling full-fledged psoriasis. K14-VEGF transgenic animals older than 5 months of age developed pronounced epidermal rete ridges and marked cutaneous inflammation (Figure 3D). In these lesions, psoriasiform hyperplasia with elongated rete ridges and anastomosis of neighboring rete ridges was found (Figure 3D), revealing a striking resemblance to fully developed psoriasis in humans (Figure 3F). It is important to note that rete ridge formation is one of the most characteristic and longest-recognized histologic features of human psoriasis and that no other transgenic mouse model results in rete ridge formation (Figure 1).

#### Hyperplastic and inflamed cutaneous blood vessels in K14-VEGF transgenic mice are similar to those observed in human psoriasis

To understand the nature of the visible skin redness in the K14-VEGF transgenic mice, we immunocytochemically stained ear sections with an antibody to an endothelial-cell-specific antigen, PECAM-1. When compared with microvessels in wild-type skin (Figure 4,A) those in 3-month-old K14-VEGF mice with wound-induced psoriasis were obviously dilated and tortuous. The superficial vascular plexus showed that the most prominent angiogenic alterations consisted of vertically oriented vascular tufts in dermal papillae, similar to human psoriasis (Figure 4B). In the unwounded skin of older K14-VEGF mice (6 months of age), these enlarged vessels became more prominent within dermal papillae that were surrounded by a hyperproliferative epidermis undergoing rete ridge anastomosis (Figure 4C). Elongated and enlarged vessels found in the dermal papillae of K14-VEGF mice have a remarkable resemblance to the long, ectatic vessel loops seen in the dermal papillae of human psoriatic skin.

Because the K14-VEGF mice exhibited enlarged and tortuous vessels in dermal papillae analogous to those seen in human



**Figure 4. Hyperplastic and inflamed cutaneous blood vessels in K14-VEGF transgenic mice.** Immunostaining was performed on cryosections of ear skin from wild-type littermate controls (A, D-E) and transgenic mice (B-C, F-G). PECAM staining showed increased vascular density mostly in the papillary dermis in wound-induced psoriasis in the 3-month-old transgenic mice (B). Enlarged vessels in 6-month-old transgenic mice showed vessels enclosed by anastomosing epidermal rete ridges (C). Immunostaining of E-selectin (G) and ICAM-1 (F) showed positive signals on dermal microvessels in transgenic mice (arrowheads). Original magnifications:  $\times 20$  (A-C); and  $\times 10$  (D-G).

psoriatic skin, we next explored whether these hyperplastic vessels also exhibited features of vascular inflammation seen in patients with psoriasis. In particular, the induction of specific endothelial cell adhesion molecules is a hallmark of the hyperplastic and inflamed vessels seen in human psoriatic skin lesions, including the induction of E-selectin (CD62E),<sup>15</sup> VCAM-1 (CD106),<sup>16</sup> and ICAM-1 (CD54).<sup>14</sup> Similar to findings in human psoriasis, the expression of these cell adhesion molecules were prominent in hyperplastic vessels in the psoriasiform skin from K14-VEGF mice (Figure 4F-G).


#### Abnormal epidermal proliferation and differentiation in K14-VEGF mice resembling that seen in human psoriasis

Epidermal analysis of the psoriasiform lesions in K14-VEGF transgenic mice revealed hyperkeratosis (increased thickness of the stratum corneum) and parakeratosis (retention of nuclei in the cornified keratinocytes) (Figure 5A). Human psoriasis is characterized by similar hyperkeratosis and parakeratosis<sup>44</sup> and by altered epidermal hyperproliferation, as reflected by thickening of the

**Table 1. Koebner phenomenon in young K14-VEGF transgenic mice**

Wild-type littermates, wounded	K14-VEGF mice, unwounded	K14-VEGF mice, wounded
<b>Rete ridge counts/unit length of epithelium</b>		
$\pm SD$ , mm	0	$2.0 \pm 1.3$
$11.3 \pm 5.2$		

Young is defined as approximately 3 months old.  
Each category of littermates consisted of 5 mice.



**Figure 5.** Abnormal epidermal proliferation and differentiation in K14-VEGF transgenic mice. Parakeratosis and hyperkeratosis were observed in H&E-stained skin sections from 6-month-old transgenic mice (A). Immunostaining of keratin K6 showed strong up-regulation throughout the epidermis (compare panels B and C) in 6-month-old transgenic mice.

epidermis and aberrant expression of hyperproliferation-associated keratins K6 and K16 throughout the epidermis, which are normally restricted to sporadic basal keratinocytes and hair follicles.<sup>45</sup> Another similarity we found between the psoriasisiform lesions of K14-VEGF mice and human psoriasis was the strong expression of K6 throughout the hyperplastic epidermis of K14-VEGF mice (Figure 5C); normal mouse skin, with the exception of hair follicles and occasional basal keratinocytes, did not express K6 (Figure 5B).

#### K14-VEGF mice exhibit epidermal microabscesses and inflammatory infiltrates characteristic of human psoriasis

Neutrophil-filled lesions resembling the epidermal microabscesses found in advanced human psoriasis were observed in the epidermis of 6-month-old K14-VEGF transgenic mice (Table 2). One type of microabscess, mimicking the location of Munro microabscesses

**Table 2. Quantitation of psoriatic phenotype in older K14-VEGF transgenic mice**

	Wild-type littermates	K14-VEGF mice
Mice with lesions, %*	0	98
Intraepidermal CD8 <sup>+</sup> T-cell counts/unit length of epithelium $\pm$ SD, mm <sup>-1</sup>	0	5.55 $\pm$ 2.10
Intraepidermal microabscesses per specimen†	0	4.2


Older is defined as older than 5 months.

\*n > 120 mice; †n = 4 mice; ‡n = 5 mice.

described in human psoriasis, was localized within the stratum corneum (Figure 6A),<sup>46,47</sup> and a second type of microabscess, resembling Kogoj microabscesses seen in human psoriasis, was localized immediately beneath the stratum corneum (Figure 6B).<sup>46,47</sup> The presence of microabscesses in human psoriatic skin is a key feature used in the clinical diagnosis of human psoriasis.<sup>46,47</sup>

Analysis of the inflammatory cell infiltrate in 3-month-old K14-VEGF mice revealed a significant increase in both mast cells (as determined by staining for toluidine blue, which stains mast cell granules; Figure 6D) and macrophages (as determined with an antibody to the murine macrophage marker F4/80 antigen (Figure 6G) when compared with wild-type littermate controls (Figure 6C-F). Further increases in mast cells and macrophages were evident as the animals aged to 6 months (Figure 6E-H).

To assess the number and distribution of CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes, we immunostained for these cells in the 3- and 6-month-old transgenic animals. Results revealed massive infiltration of CD4<sup>+</sup> T-lymphocytes localized primarily to the dermis of 3-month- (data not shown) and 6-month-old transgenic mice (Figure 6I). The overall level of CD8<sup>+</sup> T-lymphocytes that infiltrated into the transgenic skin was significantly lower than that of



**Figure 6.** K14-VEGF mice exhibit epidermal microabscesses and inflammatory infiltrates characteristic of human psoriasis. (A) Munro-like microabscess. (B) Kogoj-like microabscesses. Progressive increase of mast cell (C-E) and macrophage (F-H) density with 3-month-old (D, G) and 6-month-old (E, H) transgenic mice compared with wild-type littermates (C, F). CD4<sup>+</sup> T-lymphocytes were detected primarily in the dermis (I) and CD8<sup>+</sup> T-lymphocytes in the epidermis of 6-month-old transgenic mice (J). E indicates epidermis; D, dermis.

the CD4<sup>+</sup> T-lymphocytes. In young K14-VEGF mice, these CD8<sup>+</sup> T-lymphocytes were detected in the dermis and the epidermis (data not shown), whereas the CD8<sup>+</sup> lymphocytes translocated and became localized to the epidermis in the 6-month-old transgenic mice (Figure 6J; Table 2). This complementary localization of CD4<sup>+</sup> versus CD8<sup>+</sup> lymphocytes in dermis and epidermis is also characteristic of human psoriatic skin.

#### Treatment with VEGF Trap normalizes the psoriatic phenotype in K14-VEGF transgenic mice


Our data demonstrate that many of the histologic and immunologic hallmarks of human psoriasis appear when VEGF is chronically overexpressed in mouse epidermis. To confirm the role of VEGF in the initiation and maintenance of this psoriatic phenotype and to attempt to ameliorate it, we used a potent VEGF inhibitor, VEGF Trap.<sup>43</sup> Six K14-VEGF transgenic mice at 6 months of age with obvious psoriatic lesions were systemically treated with VEGF Trap at a dose of 25 mg/kg every 3 days for 12 days. Although similar lesions in K14-VEGF mice do not regress spontaneously or after control treatments, in 4 of the K14-VEGF mice treated with VEGF Trap, pronounced visual improvement was observed in lesions on gross inspection. The other 2 K14-VEGF mice treated with VEGF Trap displayed moderate improvement. Using enzyme-linked immunosorbent assay (ELISA) to detect antibodies raised against VEGF Trap in these animals, we detected an obvious immune response only in the latter 2 moderate responders, suggesting partial immunoneutralization of VEGF Trap in these mice (data not shown). Histologic evaluation of all 6 K14-VEGF mice treated with VEGF Trap revealed near-complete resolution of the rete ridge elongations (Figure 7A-B), normalization of epidermal architecture and diminution of parakeratosis (Figure 7C-D),

and reduction in vascular hyperplasia (Figure 7E-F). In addition, the K6 marker of aberrant epidermal differentiation was normalized by VEGF Trap treatment (Figure 7G-H), as were markers of vascular inflammation E-selectin (Figure 7I-J), ICAM-1 in basal keratinocytes and vasculature (data not shown), and CD8<sup>+</sup> T-lymphocyte distribution (Figure 7K-L).

Numerous reports have correlated the level of disease activity in psoriasis with the levels of soluble vascular adhesion molecules in the sera of patients with psoriasis, in particular soluble E-selectin that is presumably cleaved from the surface of inflamed dermal vessels.<sup>17-20</sup> Further correlating our animal model with the human condition, we find that serum levels of E-selectin are much higher in K14-VEGF mice ( $249.42 \pm 38.64$  ng/mL) than in control mice ( $37.34 \pm 7.06$  ng/mL), and, just as important, these increased levels are reduced with VEGF Trap treatment (to  $96.74 \pm 16.25$  ng/mL). Altogether, our data indicate that VEGF is continuously required to maintain the psoriasisform lesions in older K14-VEGF mice and that even longstanding disease can be dramatically reversed with VEGF blockade.

#### Discussion

The underlying pathogenic mechanism and the key molecule(s) that are causative for psoriasis have not yet been identified. Recent studies for causative agents have focused on molecular mediators of inflammation or keratinocyte growth. However, attempts to mimic human psoriasis by transgenically overexpressing such mediators in mice do not completely recapitulate the human disease in all its pathologic aspects (Figure 1). In addition, the most



**Figure 7.** VEGF Trap normalizes the psoriatic phenotype in K14-VEGF transgenic mice. Transgenic mice with severe skin lesions were injected with VEGF Trap (25 mg/kg) on days 0, 3, 7, and 12. Tissue was harvested on day 14 for histologic analysis. H&E staining of mouse ear skin treated with VEGF Trap showed clear resolution of rete ridges (compare panels A and B) and decreased parakeratosis/hyperkeratosis (compare panels C and D). Immunostaining with PECAM showed a drop-off of microvessels in the papillary dermis (compare panels E and F). Immunostaining with keratin K6 and E-selectin each showed remarkable down-regulation of signals in the epidermis (compare panels G and H), dermal capillaries (compare panels I and J), respectively. Arrowheads in panel I denote positive staining of blood vessels for E selectin. CD8<sup>+</sup> T-lymphocytes shifted localization from the epidermis to the dermis in treated animals (compare panels K and L). E indicates epidermis; D, dermis.

faithful animal model of psoriasis to date requires the transplantation of human psoriatic skin to SCID mice<sup>23</sup> (Figure 1). Our findings lend credence to earlier suggestions that vascular changes might be among the earliest markers of the human psoriatic state.<sup>7,11</sup> In particular, our studies suggest that VEGF, which has previously been shown to be dramatically elevated in human psoriatic skin,<sup>12</sup> might play a causative role in the vascular changes seen in this disease and also in epidermal and inflammatory alterations. Along these lines, we demonstrate that excess VEGF in the skin is sufficient to create a predisposition to a psoriatic phenotype and that such overexpression eventually leads to the spontaneous development of a psoriasisiform condition in mice that recapitulates human psoriasis in many of its features—not only the hyperplastic and inflammatory vascular changes but also the characteristic epidermal alterations and tissue inflammatory cell infiltrates (Figure 1). Additional emerging evidence for a role of VEGF in the etiology of psoriasis comes from recent genetic analyses showing an association between VEGF promoter polymorphisms and the development of psoriatic symptoms (M.D., personal oral communication, November 2002). The induction of psoriasis by VEGF seems to be specific in that skin-specific transgenic delivery of another angiogenic factor, Ang1, does not result in a similar phenotype.<sup>14</sup>

In our model, it is clear that excess VEGF does not immediately cause full-blown disease. It takes up to 5 to 6 months for the development of obvious spontaneous disease. Overexpression of VEGF in the adult animal skin by viral gene transfer does not induce psoriasis because short-term VEGF expression is not sufficient to induce the psoriatic phenotype. In fact, it has been shown that the injection of a nonreplicating adenoviral vector, engineered to express VEGF<sub>164</sub>, into the ears of athymic mice only temporarily induced the formation of dilated and leaky angiogenic vessels.<sup>48</sup> Thus, it seems likely that acute overexpression of VEGF creates a dilated, leaky, and inflamed cutaneous vasculature but that chronic overexpression is necessary to yield a more widespread inflammatory condition in the skin with profound epidermal changes resembling psoriasis. Although it is unclear how VEGF results in such widespread changes, it seems likely that the inflamed vasculature, which exhibits elevations in vascular adhesion molecules such as E-selectin, ICAM-1, and VCAM-1, plays a primary role by promoting the extravasation of inflammatory cells to the skin that then lend their own cytokine and chemokine mediators to the process. This inflammatory infiltrate and the tissue edema promoted by the leaky vessels may well compromise the normal barrier function of the skin, allowing the entry of exogenous antigens and further exacerbating the immune state. The creation of a diverse inflammatory milieu may then secondarily lead to epidermal alterations that seem to occur after the initial vascular and inflammatory changes in our model. Regardless of the mechanism by which chronically elevated VEGF in our model results in a psoriasisiform phenotype, the maintenance of this abnormal state remains dependent on VEGF—we show that VEGF blockade late in this process can effectively reverse almost all the

observed abnormalities. It should perhaps not be surprising, based on previous studies indicating that VEGF can act as a potent and pleiotropic inflammatory agent, that transgenic delivery of VEGF to the skin can lead to a profound inflammatory skin condition. For example, a recent *in vitro* study using human umbilical vein endothelial cells (HUVECs) showed that VEGF stimulated the expression of ICAM-1, VCAM-1, and E-selectin through nuclear factor- $\kappa$ B activation.<sup>49</sup> VEGF has also been shown to induce monocyte activation and chemotaxis through VEGF receptor-1 (Flt-1), which is expressed on monocytes.<sup>50,51</sup> In addition, VEGF has been shown to induce expression of the chemokine IL-8, which is a potent modulator of the transendothelial migration of neutrophils.<sup>52</sup>

Although we do not yet precisely understand how transgenic overexpression of VEGF eventually leads to a psoriasisiform condition in mice, it seems impossible to ignore the possibility that VEGF may play a key causative role in human psoriasis, and it seems important to follow up on this possibility and on the implications for understanding and treating the human disease. Conventional psoriasis treatments that attempt to control the inflammatory response and subsequent epidermal hyperproliferation rely on immunosuppressants and antiproliferative therapy, involving considerable toxicity often without complete resolution. The use of a specific VEGF antagonist, such as VEGF Trap, to eliminate the hyperplastic vascular phenotype, suppress the associated inflammatory state, and reduce the levels of surrogate markers (such as E-selectin) of the disease in human psoriasis may provide a novel therapeutic strategy with minimal adverse side effects. It is also important to note that some existing or emerging therapies for psoriasis may act in part by blocking the VEGF pathway. For example, calcineurin inhibition by cyclosporine or FK-506 may block VEGF production or action,<sup>53,54</sup> and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and IL-1 seem to be potent inducers of VEGF. This induction may be important for some of their pathologic actions.<sup>55,56</sup>

Our findings demonstrate that prolonged VEGF overexpression has powerful proinflammatory capabilities *in vivo* and leads to a skin phenotype resembling human psoriasis. VEGF is likely a key factor in the link between inflammation and angiogenesis. Therefore, its role should be explored in a variety of other inflammatory conditions. Furthermore, our findings substantiate emerging concerns<sup>6</sup> about potential adverse effects that might be associated with therapeutic attempts to chronically deliver VEGF for proangiogenic purposes, particularly with regard to its profound proinflammatory capabilities.

## Acknowledgments

We thank Drs Nick Gale and Virginia Hughes for maintaining transgenic mouse lines, Dr Dan Ragland for help with mast cell staining, and Drs Thomas Hawighorst and Jennifer Silva for contributing to the immunostaining. We also thank Scott Staton and Vicki Lan for image processing.

## References

- Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. *Science*. 1998;282:468-471.
- Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. *J Invest Dermatol*. 1998;111:1-6.
- Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. *Oncogene*. 1998;17:303-311.
- Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. *Science*. 1999;286:2511-2514.
- Celletti FL, Waugh JM, Arnabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. *Nat Med*. 2001;7:425-429.
- Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. *Circulation*. 2001;104:115-119.

7. Braverman IM, Sibley J. Role of the microcirculation in the treatment and pathogenesis of psoriasis. *J Invest Dermatol.* 1982;78:12-17.
8. Van de Kerkhof PC, Van Erp PE. The role of epidermal proliferation in the pathogenesis of psoriasis. *Skin Pharmacol.* 1996;9:343-354.
9. Nickoloff BJ. The immunologic and genetic basis of psoriasis. *Arch Dermatol.* 1999;135:1104-1110.
10. Nickoloff BJ. Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. *J Investig Dermatol Symp Proc.* 2000;5:67-73.
11. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. *Arch Dermatol Res.* 1985;277:352-358.
12. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. *J Exp Med.* 1994;180:1141-1146.
13. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. *Br J Dermatol.* 1999;141:1054-1060.
14. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. *J Am Acad Dermatol.* 1989;20:617-629.
15. Groves RW, Allen MH, Barker JN, Haskard DO, MacDonald DM. Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. *Br J Dermatol.* 1991;124:117-123.
16. Groves RW, Ross EL, Barker JN, MacDonald DM. Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon gamma. *J Am Acad Dermatol.* 1993;29:67-72.
17. Kowalzik L, Neuber K, Weichenthal M, Kohler I, Ring J. Elevated serum-soluble ELAM-1 levels in patients with severe plaque-type psoriasis. *Arch Dermatol Res.* 1994;286:414-416.
18. Czech W, Schopf E, Kapp A. Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis—correlation with disease activity. *Br J Dermatol.* 1996;134:17-21.
19. Krasowska D, Pietrzak A, Lecewicz-Torun B. Serum level of sELAM-1 in psoriatic patients correlates with disease activity. *J Eur Acad Dermatol Venereol.* 1999;12:140-142.
20. Szeplietowski J, Wasik F, Bialicka E, Nockowski P, Noworolska A. Soluble E-selectin serum levels correlate with disease activity in psoriatic patients. *Clin Exp Dermatol.* 1999;24:33-36.
21. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. *Immunol Today.* 1999;20:40-46.
22. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? *J Clin Invest.* 1999;104:1161-1164.
23. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. *Am J Pathol.* 1999;155:145-158.
24. Weinstein GD, Krueger JG. Overview of psoriasis. In: Weinstein GD, Gottlieb AB, eds. *Therapy of Moderate to Severe Psoriasis.* Portland, OR: National Psoriasis Foundation; 1994:1-22.
25. Barker JN, Karabin GD, Stoop TJ, Samra VJ, Dixit VM, Nickoloff BJ. Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. *J Dermatol Sci.* 1991;2:106-111.
26. Kupper TS. The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses. *J Invest Dermatol.* 1990;94(suppl):146S-150S.
27. Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. *Proc Natl Acad Sci U S A.* 1989;86:6367-6371.
28. Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. *Cell.* 2001;104:9-19.
29. Cook PW, Piepkorn M, Clegg CH, et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. *J Clin Invest.* 1997;100:2286-2294.
30. Cooper KD, Hammerberg C, Baadsgaard O, et al. Interleukin-1 in human skin: dysregulation in psoriasis. *J Invest Dermatol.* 1990;95(suppl):24S-26S.
31. Cheng J, Turksen K, Yu QC, Schreiber H, Teng M, Fuchs E. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. *Genes Dev.* 1992;6:1444-1456.
32. Groves RW, Mizutani H, Kieffler JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. *Proc Natl Acad Sci U S A.* 1995;92:11874-11878.
33. Carroll JM, Crompton T, Seery JP, Watt FM. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. *J Invest Dermatol.* 1997;108:412-422.
34. Guo L, Yu QC, Fuchs E. Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. *EMBO J.* 1993;12:973-986.
35. Blessing M, Schirmacher P, Kaiser S. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. *J Cell Biol.* 1996;135:227-239.
36. Carroll JM, Romero MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. *Cell.* 1995;83:957-968.
37. Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. *Genes Dev.* 1991;5:714-727.
38. Schon MP. Animal models of psoriasis: what can we learn from them? *J Invest Dermatol.* 1999;112:405-410.
39. Bullard DC, Scharffetter-Kochanek K, McArthur MJ, et al. A polygenic mouse model of psoriasis-like skin disease in CD18-deficient mice. *Proc Natl Acad Sci U S A.* 1996;93:2116-2121.
40. Miller RA. The Koebner phenomenon. *Int J Dermatol.* 1982;21:192-197.
41. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. *Proc Natl Acad Sci U S A.* 1999;96:14888-14893.
42. Xia YP, Zhao Y, Marcus J, et al. Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischaemia-impaired rabbit ear model and on scar formation. *J Pathol.* 1999;188:431-438.
43. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci U S A.* 2002;99:11393-11398.
44. Weinstein GD, Frost P. Abnormal cell proliferation in psoriasis. *J Invest Dermatol.* 1968;50:254-259.
45. Stoler A, Duvic M, Fuchs E. Unusual patterns of keratin expression in the overlying epidermis of patients with dermatofibromas: biochemical alterations in the epidermis as a consequence of dermal tumors. *J Invest Dermatol.* 1989;93:728-738.
46. Elder D, Elenitasas R, Jaworsky C, Johnson B. Algorithmic classification of skin disease for differential diagnosis. In: *Histopathology of the skin.* New York, NY: Lippincott-Raven; 1997:156-163.
47. Altman E, Kamino H. Diagnosis: psoriasis or not? what are the clues? *Semin Cutan Med Surg.* 1999;18:25-35.
48. Sundberg C, Nagy JA, Brown LF, et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. *Am J Pathol.* 2001;158:1145-1160.
49. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. *J Biol Chem.* 2001;276:7614-7620.
50. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor fit-1. *Blood.* 1996;87:3336-3343.
51. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Fit-1 mediates biological activities: implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. *J Biol Chem.* 1996;271:17629-17634.
52. Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via upregulation of interleukin-8 in human brain microvascular endothelial cells. *J Biol Chem.* 2002;277:10445-10451.
53. Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. *J Exp Med.* 2001;193:607-620.
54. Cho ML, Cho CS, Min SY, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. *Arthritis Rheum.* 2002;46:1202-1209.
55. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. *Arthritis Rheum.* 1998;41:1258-1265.
56. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. *Mol Pathol.* 1997;50:225-233.